Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2000, p. 3896-3905, Vol. 20, No. 11
Department of Pharmacology and Therapeutics,
Medical College of Ohio, Toledo, Ohio 43614
Received 13 January 2000/Returned for modification 29 February
2000/Accepted 7 March 2000
pp120 (Ceacam 1) undergoes ligand-stimulated phosphorylation by the
insulin receptor, but not by the insulin-like growth factor 1 receptor
(IGF-1R). This differential phosphorylation is regulated by the C
terminus of the
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Differential Effects of pp120 (Ceacam 1) on the
Mitogenic Action of Insulin and Insulin-Like Growth Factor 1 Are
Regulated by the Nonconserved Tyrosine 1316 in the Insulin
Receptor
-subunit of the insulin receptor, the least
conserved domain of the two receptors. In the present studies, deletion
and site-directed mutagenesis in stably transfected hepatocytes derived
from insulin receptor knockout mice (IR
/
) revealed that
Tyr1316, which is replaced by the nonphosphorylatable
phenylalanine in IGF-1R, regulated the differential phosphorylation of
pp120 by the insulin receptor. Similarly, the nonconserved
Tyr1316 residue also regulated the differential effect of
pp120 on IGF-1 and insulin mitogenesis, with pp120 downregulating the
growth-promoting action of insulin, but not that of IGF-1. Thus, it
appears that pp120 phosphorylation by the insulin receptor is required
and sufficient to mediate its downregulatory effect on the mitogenic action of insulin. Furthermore, the current studies revealed that the C
terminus of the
-subunit of the insulin receptor contains elements
that suppress the mitogenic action of insulin. Because IR
/
hepatocytes are derived from liver, an
insulin-targeted tissue, our observations have finally resolved the
controversy about the role of the least-conserved domain of insulin and
IGF-1Rs in mediating the difference in the mitogenic action of their
ligands, with IGF-1 being more mitogenic than insulin.
*
Corresponding author. Mailing address: Medical College
of Ohio, 3035 Arlington Ave., HSci Building, Room 270, Toledo, OH
43614. Phone: (419) 383-4059. Fax: (419) 383-2871. E-mail:
snajjar{at}mco.edu.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|